Exelixis (NASDAQ: EXEL) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Exelixis to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and risk.

Valuation and Earnings

This table compares Exelixis and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Exelixis $191.45 million -$70.22 million 53.92
Exelixis Competitors $284.28 million $33.78 million 74.47

Exelixis’ peers have higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Exelixis has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Comparatively, Exelixis’ peers have a beta of 8.40, suggesting that their average share price is 740% more volatile than the S&P 500.

Profitability

This table compares Exelixis and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Exelixis 36.80% 105.47% 27.22%
Exelixis Competitors -5,311.45% -218.34% -39.53%

Analyst Ratings

This is a summary of recent ratings and price targets for Exelixis and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exelixis 0 6 6 0 2.50
Exelixis Competitors 858 3204 11630 231 2.71

Exelixis currently has a consensus price target of $31.29, suggesting a potential upside of 18.42%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.48%. Given Exelixis’ peers stronger consensus rating and higher possible upside, analysts plainly believe Exelixis has less favorable growth aspects than its peers.

Institutional and Insider Ownership

81.2% of Exelixis shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.1% of Exelixis shares are held by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Exelixis peers beat Exelixis on 9 of the 13 factors compared.

Exelixis Company Profile

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company’s CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company’s XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Receive News & Stock Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related stocks with our FREE daily email newsletter.